Portable Quadruplex PCR System Unveiled
|
By LabMedica International staff writers Posted on 08 Mar 2018 |

Image: The Maverick portable quadruplex PCR system (Photo courtesy of Anitoa Systems).
An early-access program for a portable real time quantitative polymerase chain reaction (qPCR) system has been launched. The platform weighs one kilogram and can run quadruplex qPCR on each of four samples simultaneously.
The system combines low-light complementary metal–oxide–semiconductor, or CMOS, biosensors with microfluidics to miniaturize medical devices at a reduced cost. The system is initially targeting the platform toward the research and applied markets, and eventually diagnostics.
The system is called Maverick (Anitoa Systems, Menlo Park, CA) and is an ultra-portable, Bluetooth(R) 2.0 enabled qPCR system that is compatible with standard qPCR assays, with up to 4-channel multiplexing. Target applications are rapid, on-the-site nucleic acid test of infectious diseases; blood screening; food safety and environmental monitoring. Maverick features a 4-channel fluorescence optical system based on Anitoa ULS24 Ultra-low light Bio-imaging chip. With no internal moving parts, Maverick is rugged and requires no calibration to operate.
In terms of the thermal cycler itself, the instrument uses standard Peltier cycling, but Anitoa has adapted techniques from the computing industry to miniaturize its systems. For example, it used technologies to manage heat that are commonly used in handset manufacturing, and heat sink innovations from the personal computing industry. Overall, the system can heat at 5° C per second and cool at 4° C per second, enabling a sub-30-minute test cycle. The Maverick is different from some of the other available systems in that it is real-time PCR, so it is quantitative, and it can be multiplexed with optical channels enabling detection of up to four targets per tube. The company plans for a commercial release of the Maverick in the summer, and is currently supplying beta products as part of its early-access program.
Zhimin Ding, PhD, the CEO of Anitoa Systems, said, “Our system is a direct imaging system, so there is no need for calibration in the field. Subsequent image analysis software quantifies the reaction. In contrast, in systems that use a photodiode to pick up signal, alignment of the diode and tubes needs to be accurate, and re-calibrated if the machine is jolted or shaken. Compared to other systems, the Maverick is lighter and more portable, and, since Anitoa controls the manufacture of its optical components, it can be more cost competitive than a number of other systems. It will cost between USD 3,500 and USD 6,000, depending on the number of optical channels a customer needs in the instrument.” The device was shown at the Molecular Medicine Tri-Conference held February 11-16, 2018, in San Francisco, CA, USA.
The system combines low-light complementary metal–oxide–semiconductor, or CMOS, biosensors with microfluidics to miniaturize medical devices at a reduced cost. The system is initially targeting the platform toward the research and applied markets, and eventually diagnostics.
The system is called Maverick (Anitoa Systems, Menlo Park, CA) and is an ultra-portable, Bluetooth(R) 2.0 enabled qPCR system that is compatible with standard qPCR assays, with up to 4-channel multiplexing. Target applications are rapid, on-the-site nucleic acid test of infectious diseases; blood screening; food safety and environmental monitoring. Maverick features a 4-channel fluorescence optical system based on Anitoa ULS24 Ultra-low light Bio-imaging chip. With no internal moving parts, Maverick is rugged and requires no calibration to operate.
In terms of the thermal cycler itself, the instrument uses standard Peltier cycling, but Anitoa has adapted techniques from the computing industry to miniaturize its systems. For example, it used technologies to manage heat that are commonly used in handset manufacturing, and heat sink innovations from the personal computing industry. Overall, the system can heat at 5° C per second and cool at 4° C per second, enabling a sub-30-minute test cycle. The Maverick is different from some of the other available systems in that it is real-time PCR, so it is quantitative, and it can be multiplexed with optical channels enabling detection of up to four targets per tube. The company plans for a commercial release of the Maverick in the summer, and is currently supplying beta products as part of its early-access program.
Zhimin Ding, PhD, the CEO of Anitoa Systems, said, “Our system is a direct imaging system, so there is no need for calibration in the field. Subsequent image analysis software quantifies the reaction. In contrast, in systems that use a photodiode to pick up signal, alignment of the diode and tubes needs to be accurate, and re-calibrated if the machine is jolted or shaken. Compared to other systems, the Maverick is lighter and more portable, and, since Anitoa controls the manufacture of its optical components, it can be more cost competitive than a number of other systems. It will cost between USD 3,500 and USD 6,000, depending on the number of optical channels a customer needs in the instrument.” The device was shown at the Molecular Medicine Tri-Conference held February 11-16, 2018, in San Francisco, CA, USA.
Latest Microbiology News
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
- Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
- New Diagnostic Method Confirms Sepsis Infections Earlier
- New Markers Could Predict Risk of Severe Chlamydia Infection
- Portable Spectroscopy Rapidly and Noninvasively Detects Bacterial Species in Vaginal Fluid
- CRISPR-Based Saliva Test Detects Tuberculosis Directly from Sputum
- Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People
- Saliva Test Detects Implant-Related Microbial Risks
- New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








